AstraZeneca Oncology iSciences Retains The Chase Group for Chief Scientific Leadership Position Jul 15, 2015
The Chase Group has been retained to conduct a search to identify an industry leader to serve as the Chief Scientific Leader for their iSciences immune-oncology small molecule early development team. The Chief Scientist will be responsible for leading the strategy for AstraZeneca’s immune-oncology development efforts, along with being the interface with the biologics immune-oncology efforts at MedImmune. For more information, please contact Joyce Tucker at 913.663.3100 or joyce@chasegroup.com.
